MINIMUM bio
Fast and agnostic drug target ID for pharma
At a glance
-
Development stage
Prototype developed
-
Investment stage
Seed
-
UNSW affiliation
Co-located company
-
Technology readiness level
TRL 8
-
Female led
Co-led
MINIMUM bio are developing a powerful drug target search engine.
Their unique drug target identification platform will save years and hundreds of millions of dollars in drug development costs and lead to safer and more effective medications to alleviate human suffering.
-
MINIMUM bio’s flagship Mercurious® harnesses the power of a vaccine discovery platform (phage display) and repurposes it for drug target discovery. The resulting product combines advances in molecular biology, next generation sequencing and machine learning into a single integrated architecture for rapid and agnostic drug target discovery with the goal of accelerating the rate of drug development.
-
Drugs cost too much and take too long to develop (12 years and US$3B+), with 80% of candidates failing to launch after clinical trials. A major reason for this, is that pharma often doesn’t fully understand how their drug candidates work which is a consequence of expensive and ineffective target identification platforms.
-
Partnering with global pharmaceutical companies to help develop safer and more effective drugs, faster.
Partnering with biotechs and academia to solve real world problem by identifying new drug targets.
Licensing our early-stage assets to Global Pharma for further development.
Providing a service to Pharma and biotech globally.
-
Pre-Seed funding (AU$1.5M) from a top 5 global pharma.
Successful Accelerating Commercialisation (AC) and NSW MVP grants ($1M).
First patent lodged September 2025.
Pilot projects completed with Abbvie (Chicago) and WEHI (Melbourne).
Collaborative agreements with Evogene (Israel), MCRF (Japan), a top Pharma (USA) and UT Austin (USA).
5 peer reviewed publications outlining our tech.
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.